REFERENCES
- Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J. Clin. 2006; 56(2)106–130
- Effects o f. chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365(9472)1687–1717
- Weineke M., Dienst E. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-Oncology 1995; 4: 61–66
- van Dam F. S., Schagen S. B., Muller M. J., et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J. Natl. Cancer Inst. 1998; 90(3)210–218
- Schagen SB., van Dam FS., Muller MJ., Boogerd W., Lindeboom J., Bruning PF. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999; 85(3)640–650
- Schagen SB, Muller MJ., Boogerd W., Van Dam FS. Cognitive dysfunction and chemotherapy: neuropsychological findings in perspective. Clin. Breast Cancer 2002; 3: S100–108, (Suppl 3)
- Brezden CB, Phillips KA., Abdolell M., Bunston T., Tannock IF. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J. Clin. Oncol. 2000; 18(14)2695–2701
- Ahles TA, Saykin AJ., Furstenberg CT., et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J. Clin. Oncol. 2002; 20(2)485–493
- Tchen N., Juffs HG., Downie FP., et al. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J. Clin. Oncol. 2003; 21(22)4175–4183
- Castellon SA, Ganz PA., Bower JE., Petersen L., Abraham L., Greendale GA. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J. Clin. Exp. Neuropsychol. 2004; 26(7)955–969
- Wefel JS, Lenzi R., Theriault RL., Davis RN., Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer I 2004; 100(11)2292–2299
- Shilling V., Jenkins V., Morris R., Deutsch G., Bloomfield D. The effects of adjuvant chemotherapy on cognition in women with breast cancer–preliminary results of an observational longitudinal study. Breast 2005; 14(2)142–150
- Hurria A., Rosen C., Hudis C., et al. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. J. Am. Geriatr. Soc. 2006; 54(6)925–931
- Donovan KA, Small BJ., Andrykowski MA., Schmitt FA., Munster P., Jacobsen PB. Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma. Cancer 2005; 104(11)2499–2507
- Jenkins V., Shilling V., Deutsch G., et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br. J. Cancer 2006; 94(6)828–834
- Silverman DH, Dy CJ., Castellon SA., et al. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res. Treat. 2006
- Kreukels BP, Schagen SB., Ridderinkhof KR., Boogerd W., Hamburger HL., van Dam FS. Electrophysiological correlates of information processing in breast-cancer patients treated with adjuvant chemotherapy. Breast Cancer Res. Treat. 2005; 94(1)53–61
- Shilling V., Jenkins V., Fallowfield L., Howell A. The effects of oestrogens and anti-oestrogens on cognition. Breast 2001; 10(6)484–491
- Jenkins V., Shilling V., Fallowfield L., Howell A., Hutton S. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psycho-Oncology 2004; 13(1)61–66